Baseline characteristics of patients
| Characteristics | Knee OA (n = 603) | Hip OA (n = 211) | ||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| *Non-steroidal anti-inflammatory drugs (before the start of the study); †other than NSAIDs (before the start of the study); ‡chondroitin sulphate, diacerhein, or avocado/soybean unsaponifiables. | ||||
| Age (years) | 67.9 | 10.2 | 64.6 | 10.2 |
| Weight (kg) | 75.5 | 13.8 | 71.3 | 12.3 |
| Height (cm) | 163.8 | 8.5 | 164.7 | 8.4 |
| Body mass index (kg/m2) | 28.1 | 4.8 | 26.2 | 3.8 |
| Disease duration (years) | 4.7 | 5.8 | 3.3 | 4.6 |
| Pain score (0–100 mm VAS) | ||||
| Week 0 | 59.3 | 16.2 | 56.7 | 16.5 |
| Change (week 0–week 4) | −24.9 | 21.5 | −20.0 | 21.7 |
| Patient global assessment (0–100 mm VAS) | ||||
| Week 0 | 59.6 | 18.3 | 58.0 | 19.3 |
| Change (week 0–week 4) | −24.7 | 24.0 | −20.6 | 23.2 |
| WOMAC function score (0–100) | ||||
| Week 0 | 42.8 | 16.1 | 44.4 | 16.5 |
| Change (week 0–week 4) | −11.6 | 13.9 | −10.4 | 13.6 |
| No | % | No | % | |
| Female sex | 421 | 69.8 | 133 | 63.0 |
| Kellgren & Lawrence grade | ||||
| II | 108 | 17.9 | 33 | 15.7 |
| III | 268 | 44.4 | 111 | 52.9 |
| IV | 227 | 37.7 | 66 | 31.4 |
| NSAID* intake during past 4 weeks | 178 | 29.7 | 69 | 32.7 |
| Analgesic treatment** | 344 | 57.2 | 14.1 | 67.1 |
| Symptomatic slow-acting drug intake*** | 209 | 34.8 | 90 | 42.9 |